Partner & Head of Sagard Royalty Partners
David MacNaughtan has served as a Partner at Sagard and Head of Sagard Healthcare Royalty Partners since 2019. David is responsible for overseeing Sagard’s healthcare royalties strategy to invest in approved and commercialized biopharmaceuticals, diagnostics, and medical devices that are protected by strong intellectual property. Alongside Ali Alagheband and Raja Manchanda, he co-leads the Sagard Healthcare Royalty Partners team in their management of the investment process, including origination, due diligence, execution, and portfolio management. David is a member of the Sagard Healthcare Royalty Partners investment committee and is based in Toronto, Canada. David has known Ali for over 15 years and worked with him at DRI Capital for 7 years. He has known Raja for over a decade and worked with him at DRI Capital for two years.
Prior to Sagard, David was a Senior Principal with CPP Investment Board leading their intellectual property investment strategy under the direction of Adam Vigna, now Chief Investment Officer at Sagard. David has over 25 years of experience in the biopharmaceutical industry, with roles in operations, business development, and finance, including over 15 years of investment experience with royalty-based opportunities.
David holds a B.Sc. and M.Sc. in Applied Science from Queen’s University and an MBA from the University of Toronto, Rotman School of Business.